TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Electroacupuncture Combined With Antidepressants for Post-stroke Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* most recently experience an ischemic or hemorrhagic stroke, documented by cerebral computed topographic scanning or magnetic resonance imaging~* develop significant depression, with a HAMD-17 score of 16 or greater~Exclusion Criteria:~* presence of severe aphasia, especially fluent aphasia~* presence of severe cognitive dysfunction, indicated the Mini-mental State Examination (MMSE) score of \< 18~* had a history of psychiatric illness other than depression~* presence of another chronic disorder, including severe Parkinson's disease, cardiac disease, cancers, epilepsy, or chronic alcoholism~* impaired hepatic or renal function~* have bleeding tendency

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DCEAS (Type: EXPERIMENTAL): Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
- n-CEA (Type: PLACEBO_COMPARATOR): Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 15 obese men (BMI\>30), aged 18 to 55, with glomerular hyperfiltration (creatinine clearance\>130 ml/min)) and 10 normal body weight men (BMI\<25), aged 18 to 55.~Exclusion Criteria:~* Heart failure, CKD, COPD~* Known allergy to furosemide, acetazolamide, inulin or amino-hippurate~* Pharmacologic treatment for hypertension, cardiac disease, diabetes mellitus~* Treatment with corticosteroids, antiepileptics or NSAID

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Furosemide first, then Acetazolamide (Type: EXPERIMENTAL): Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
- Acetazolamide first, then Furosemide (Type: EXPERIMENTAL): Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)~* BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and \<50;~* Available for the duration of the treatment and follow-up (20 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials;~* Able to travel to study location (New Haven, CT) for weekly visits.~Exclusion Criteria:~* Currently taking anti-depressant medications;~* Currently taking opioid pain medications or drugs;~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa, bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BWL + NB medication (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
- BWL + Placebo (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
- NB medication (Type: EXPERIMENTAL): Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, greater than 8 years of age and a weight of more than 35 kilograms.~* Patients with current bacterial infections who have not responded to other available appropriate antibiotic therapies.~* Patient must give informed consent.~Exclusion Criteria:~* Patients with an expected survival of less than 2 weeks.~* Patients who have been designated as Do Not Resuscitate.~* Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents.~* Pregnant women or nursing mothers.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Dental Vibe Injection Comfort System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: Able to volunteer for dental anesthesia -~Exclusion Criteria: Non volunteer~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DV3 with first LB injection (Type: ACTIVE_COMPARATOR): Use of Dental Vibe with first long buccal block
- DV3 with first LB and with IAN (Type: ACTIVE_COMPARATOR): Dental Vibe with first long buccal injection and inferior alveolar block
- DV3 with 2nd LB (Type: EXPERIMENTAL): Use of DentalVibe with 2nd Long Buccal injection
- DV3 with 2nd LB and IAN (Type: EXPERIMENTAL): Use of DentalVibe with 2nd long buccal and inferior alveolar nerve block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Midodrine for Prophylaxis Against Post Spinal Hypotension in Elderly Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients (\>65).~* ASA I-II-III.~* Scheduled for hip joint surgery under spinal anaesthesia~Exclusion Criteria:~* • Uncontrolled hypertension~  * Liver cell failure (child B or C).~ * Chronic renal failure on regular dialysis~ * Contraindications of spinal anaesthesia~ * History of allergy to midodrine~ * Cardiac morbidities (impaired contractility with ejection fraction \< 50%, heart block, arrhythmias, tight valvular lesions).~ * Acute renal disease, urinary retention~ * Patients on negative chronotropic drugs (such as beta blocker) or vasoconstrictor~ * Patients with glaucoma

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control group (Type: PLACEBO_COMPARATOR): oral metoclopramide 10 mg, Metoclopramide tablet was chosen as a placebo because it has the same appearance of midodrine tablet with no cardiovascular effects
- Midodrine group (Type: ACTIVE_COMPARATOR): oral midodrine tablet (5 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant at least 1 year prior~* Subjects with a functioning renal allograft with calculated glomerular filtration rate (GFR) ≥40mL/min (Nankivell method) and proteinuria ≤500mg/day.~* Stable on cyclosporine or tacrolimus-based multi-drug immunosuppressive regimen~* History of NMSC within last 3 years~Exclusion Criteria:~* History of other cancer within last 3 years~* NMSC with metastatic disease or more than 20 NMSC lesions in last 12 months~* Multiple organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Conversion to a sirolimus-based regimen
- 2 (Type: ACTIVE_COMPARATOR): Continuation of a CNI-based regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.~* Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.~* Use of one (1), but no more than two (2) concomitant marketed antiepileptic drugs (AEDs) at the time of trial entry.~Exclusion Criteria:~* Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.~* Presence of known pseudoseizures within the last year.~* Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.~* Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): Subjects received open-label Levetiracetam.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Poorly Controlled Type 2 Diabetes (HbA1c \> 7%)~* Advanced Chronic Periodontitis~* Presence of 15 teeth~Exclusion Criteria:~* Use on antiinflammatory drugs~* Use of antibiotics less then 6 months before therapy~* Smokers~* Positive for HIV~* Periodontal treatment less then 6 months before therapy~* Advanced complications of Diabetes

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Systemic Doxycycline (Type: ACTIVE_COMPARATOR): None
- aPDT+ Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HD12 for Advanced Stages

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin´s lymphoma (histologically proven)~* CS(PS) IIB with one or both of the risk factors:~  1. bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter)~ 2. extranodal involvement~* CS(PS) III, IV~* written informaed consent~Exclusion Criteria:~* Leukocytes \<3000/microl~* Platelets \<100000/microl~* Hodgkin´s Disease as composite lymphoma~* Activity index (WHO) \< grade 2

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Escalating Ketamine Doses and Pre-emption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Consecutive patients, who were scheduled to undergo general or orthopedic oncologic surgery under general anesthesia~Exclusion Criteria:~1. allergy to opioids, ketamine or non-steroidal anti-inflammatory drugs (NSAIDs)~2. history of lasting chronic pain or psychiatric disorders or had used opioids or psychotropic drugs of any sort during the past two weeks~3. soldiers and pregnant women

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Set 1 (Type: ACTIVE_COMPARATOR): group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
- set 2 (Type: ACTIVE_COMPARATOR): 2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
- set 3 (Type: ACTIVE_COMPARATOR): 3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Smoking Treatment Programs for Lighter Smokers - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Light smokers (6-15 cigarettes per day~Inclusion Criteria:~Mentally and physically stable, non-pregnant, light smokers (6-15 cigarettes per day)~Exclusion Criteria:~Please contact site for more information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1: Bup+MM (Type: EXPERIMENTAL): bupropion and MM counseling with placebo patch
- 2 Bup+Mayo (Type: EXPERIMENTAL): bupropion and Mayo counseling with placebo patch.
- 3 Patch+MM (Type: PLACEBO_COMPARATOR): patch and MM counseling with placebo pills
- 4 Patch+Mayo (Type: EXPERIMENTAL): patch and Mayo counseling with placebo pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Active Vitamin D, ED-71 for Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoporotic patients who meet any of the following condition:~  1. with at least one fragility fracture,~ 2. above 70 year-old with bone mineral density below 70% young adult mean,~ 3. with bone mineral density below 60% young adult mean~* Women three years or more after menopause or men~Exclusion Criteria:~* Current disorders such as primary hyperparathyroidism, Cushing's syndrome,gonadal insufficiency, poorly controlled diabetes mellitus or other causes of secondary osteoporosis~* A history or suspicion of active urolithiasis at any time~* Use of bisphosphonates in the past 12 months~* Use of medications known to affect bone in the past 2 months~* Abnormal serum calcium, urinary calcium, serum creatinine or liver function tests

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Environments for Vestibular Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18 or older)~* Clinical diagnosis of chronic (3 months and longer) unilateral peripheral vestibular hypofunction~* Patients will be included based on the presence of a positive head thrust test, head shaking nystagmus, spontaneous nystagmus, and/or canal paresis \> 25% if a caloric test is available.~* Included patients must present with at least two positive items on the VVAS~Exclusion Criteria:~Patients will be excluded for prior vestibular rehab, bilateral or unstable vestibular loss or another neurological condition, active benign paroxysmal positional vertigo, acute orthopaedic injuries, peripheral neuropathy, hearing impairment, or visual impairment not corrected with glasses.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virtual Reality (Type: EXPERIMENTAL): Progressive immersive training with the virtual reality app Scenes: start from most salient to the patient, eventually do all Duration: start at 60 seconds, increase over time up to 3 minutes per scene Complexity: start minimal, gradually increase up to most complex Tasks: standing with diverse base of support (BOS), head turns (progress with speed, planes); stepping, turning 8 weeks, 1 visit per week, 30 minutes long In home: Gait and balance exercises, No exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long
- Traditional Vestibular Rehabilitation (Type: ACTIVE_COMPARATOR): Progressive gait, gaze stability and balance exercises Gait: walking with head turns, progress with range, speed and planes of head movement; change of walking BOS: wide, normal, tandem Gaze: focus on a target while moving head side to side / up down. Progress with speed, duration, busier background, standing to walking.~Balance: standing balance tasks, progress with BOS (wide to narrow to tandem), support surface, eyes closed, duration, head turns.~8 weeks, 1 visit per week, 30 minutes long In home: Gait, gaze stability and balance exercises, including exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CKD 3-4 Age 18-80~Exclusion Criteria:~* Recent MI, CVA, malignancy active infection active inflammation High calcium already on Viatmin D therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: EXPERIMENTAL): Cholecalciferol 300,000 twice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete